Earnings summaries and quarterly performance for Century Therapeutics.
Executive leadership at Century Therapeutics.
Board of directors at Century Therapeutics.
Research analysts covering Century Therapeutics.
Recent press releases and 8-K filings for IPSC.
Hopstem Receives FDA Approval for Accelerated hNPC01 Clinical Development
IPSC
Product Launch
New Projects/Investments
- Hopstem Biotechnology Inc. has received FDA approval to initiate a dose-bridging, randomized-controlled, double-blinded, Phase 2 clinical trial in the U.S. for its core product, hNPC01 Injection, targeting chronic motor dysfunction due to ischemic stroke.
- The FDA granted an accelerated clinical development pathway, allowing the Phase 2 trial to expand into a combined Phase 2/3 adaptive confirmatory clinical development program, which is expected to significantly shorten the product's time-to-market.
- This approval is based on positive Phase 1 clinical trial data from China, with the FDA recognizing the quality, safety, and efficacy of hNPC01 and waiving redundant U.S. Phase 1 development.
- This marks the first instance in the pluripotent stem cell field where U.S. Phase 1 clinical trials are waived based on Chinese Phase 1 data, and the first China-developed pluripotent stem cell product approved overseas to bridge into a pivotal clinical trial.
Jan 21, 2026, 7:46 AM
Century Therapeutics Details Clinical Pipeline Progress and Cash Runway Extension
IPSC
New Projects/Investments
Guidance Update
- Century Therapeutics is advancing its iPSC derived cell therapies, with CNTY-813 for Type 1 Diabetes and CNTY-308 for B-cell-mediated diseases in IND-enabling studies.
- Patient enrollment is ongoing for CNTY-101 in a Phase 1/2 CARAMEL IST for autoimmune diseases, with preliminary clinical data expected in 2026.
- CNTY-813 IND submission is planned for 2026, with initial clinical data expected in 2027, and CNTY-308 is expected to enter the clinic in 2026.
- The company has extended its cash runway beyond planned key clinical milestones.
Jan 12, 2026, 2:05 PM
CERo Therapeutics Provides Clinical Update on CertainT-1 Trial and Expands Study Cohorts
IPSC
New Projects/Investments
- CERo Therapeutics announced a clinical update for its CertainT-1 trial of CER-1236, initially focused on acute myeloid leukemia (AML).
- The first cohort demonstrated cell expansion with no CRS, ICANS, or treatment-related adverse events.
- A patient with myelodysplastic syndrome (MDS) that progressed to AML showed a 61-day platelet transfusion-free interval after CER-1236 treatment.
- The company has filed an amendment with the FDA to expand the CertainT-1 trial to include advanced MDS and myelofibrosis (MF) as additional cohorts.
- CERo will host a conference call today, January 7, 2026, at 5:00 PM ET, to discuss the progress and go-forward strategy.
Jan 7, 2026, 2:09 PM
Century Provides Updates on iPSC-Derived Cell Therapy Programs and Financial Outlook
IPSC
New Projects/Investments
Guidance Update
- Century is advancing its induced pluripotent stem cell (iPSC)-derived cell therapies, including CNTY813 for Type 1 diabetes, CNTY308 for autoimmune diseases, and CNTY-101 for multiple autoimmune diseases.
- A key differentiator is the proprietary Alloevasion 5.0 technology, which aims to enable cell therapies to function without heavy immunosuppression, a significant barrier in current treatments.
- Initial safety data for CNTY-101 from the investigator-sponsored Phase 1 Carmel study in autoimmune diseases is anticipated on December 5th at the 14th Annual BMT and Cell Therapy Workshop.
- The company plans to submit an Investigational New Drug (IND) application for CNTY813 as early as 2026 and initiate clinical trials for CNTY308 in 2026.
- Century's cash runway is projected to last into Q4 2027, providing approximately two years of funding.
Dec 3, 2025, 3:00 PM
Century Therapeutics Provides Pipeline and Financial Updates
IPSC
New Projects/Investments
Guidance Update
- Century Therapeutics is advancing CNTY813, an iPSC-derived beta islet cell program for type 1 diabetes, with plans to move to IND-enabling stages by the end of 2025 and submit an IND as early as 2026.
- The company expects to initiate clinical trials for CNTY-308, a CD19 CAR-iT cell therapy for B-cell-mediated autoimmune diseases, in 2026.
- Initial safety data from the investigator-sponsored Carmel study of CNTY-101 (CD19 CAR-NK) in autoimmune diseases is anticipated to be presented on December 5th at the 14th Annual BMT and Cell Therapy Workshop.
- Century reported a cash balance of $133 million at the end of Q3, providing a cash runway into Q4 2027.
Dec 3, 2025, 3:00 PM
Century Therapeutics Announces New Type 1 Diabetes Program and Q3 2025 Financial Results
IPSC
Product Launch
Guidance Update
Earnings
- Century Therapeutics announced its new iPSC-derived beta islet cell program, CNTY-813, for Type 1 diabetes, with IND-enabling studies expected to begin by year-end 2025 and an IND submission planned for 2026. Additionally, CNTY-308 is advancing through IND-enabling studies for planned clinical study initiation in 2026, and initial clinical data for CNTY-101 from the CARAMEL Phase 1/2 IST is anticipated in December 2025.
- For the third quarter ended September 30, 2025, Century Therapeutics reported a net loss of $34.4 million and R&D expenses of $22.5 million. The company estimates its cash runway will extend into the fourth quarter of 2027.
Nov 13, 2025, 12:52 PM
Century Therapeutics Reports Q3 2025 Financial Results and Business Update
IPSC
Earnings
New Projects/Investments
- Century Therapeutics reported a net loss of $34.4 million for the three months ended September 30, 2025, and held $132.7 million in cash, cash equivalents, and marketable securities as of that date. The company estimates its cash runway will extend into the fourth quarter of 2027.
- The company announced its lead iPSC derived beta islet program, CNTY-813, for Type 1 diabetes, with IND-enabling studies expected to initiate by year-end 2025 and an IND submission planned in 2026.
- CNTY-308 is advancing through IND-enabling studies, with clinical study initiation planned for 2026.
- Clinical development of CNTY-101 will continue in the CARAMEL investigator-sponsored trial (IST), with initial clinical data expected in December 2025, while the company-sponsored CALiPSO-1 trial has been discontinued as part of clinical development re-prioritization efforts.
Nov 13, 2025, 12:30 PM
Century Therapeutics Provides Update on Clinical Pipeline and Cash Runway
IPSC
New Projects/Investments
Guidance Update
Product Launch
- Century Therapeutics (IPSC) is progressing its iPSC-based platform, with its lead clinical program, CNTY-101 (an NK cell-based therapy for autoimmune diseases), expected to provide trial outcome updates by the end of 2025.
- The company's preclinical pipeline includes CNTY-308, an alpha-beta T cell program from iPSC cells targeting B-cell-mediated diseases, which is in IND-enabling studies and planned to enter the clinic in mid-2026.
- Century Therapeutics has extended its cash runway through 2027 following a company restructuring.
- The company highlighted its advanced alloevasion technologies, including alloevasion 5.0, which features a universal NK cell defense and humoral protection, integrated into its preclinical products.
Oct 21, 2025, 4:20 PM
Century Therapeutics Provides Pipeline and Technology Update
IPSC
New Projects/Investments
Guidance Update
- Century Therapeutics (IPSC) is advancing its clinical programs, including SENTURY-one 101 (NK cell-based therapy for autoimmune diseases) in two trials, with data readouts anticipated by the end of 2025.
- The company's preclinical pipeline features SENTURY-three zero eight, an alpha beta T cell program from iPS cells, slated to enter the clinic in mid-2026, and a novel non-immune cell program.
- Century Therapeutics has extended its cash runway through 2027 due to recent restructuring efforts.
- Key technological advancements include the AlloEvasion 5.0 platform, which incorporates a CD-300A taser for universal NK cell defense and an IgG degrading protease for humoral protection.
Oct 21, 2025, 4:20 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more